Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced that Dr. Carl Morris, Chief Scientific Officer, will participate in a panel discussion on Duchenne muscular dystrophy (DMD) at the virtual Guggenheim Healthcare Talks on April 1, 2021, from 9:00 a.m. to 9:50 a.m. EDT. The panel, titled “The more we learn the less we know about DMD,” will explore advancements in DMD therapies. A live webcast of the event will be available on the company’s investor relations website, with a replay accessible afterward.

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled “The more we learn the less we know about DMD—From micro-dystrophin, to morpholinos, and small molecules” will be held on Thursday, April 1, 2021 from 9:00 a.m. - 9:50 a.m. Eastern Time.

A live webcast of the presentation will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

When will Dr. Carl Morris participate in the Guggenheim Healthcare Talks for Solid Biosciences?

Dr. Carl Morris will participate in the panel discussion on April 1, 2021, from 9:00 a.m. to 9:50 a.m. EDT.

What is the topic of the panel discussion featuring Solid Biosciences at the Guggenheim Healthcare Talks?

The panel discussion is titled 'The more we learn the less we know about DMD,' focusing on Duchenne muscular dystrophy.

Where can I watch the Solid Biosciences panel discussion live?

You can watch the live webcast on Solid Biosciences' investor relations website under the Events page.

What is the focus of Solid Biosciences as a company?

Solid Biosciences focuses on advancing therapies for Duchenne muscular dystrophy, specifically through gene therapy.

What is the significance of the panel discussion at the Guggenheim Healthcare Talks for Solid Biosciences?

The panel discussion highlights advancements in DMD therapies and features insights from industry experts.